Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 13,820 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the transaction, the chief financial officer directly owned 250,996 shares of the company’s stock, valued at $1,912,589.52. The trade was a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Wednesday, January 28th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $8.45, for a total transaction of $14,322.75.

Relay Therapeutics Price Performance

NASDAQ RLAY traded up $0.06 on Thursday, hitting $7.71. 1,788,553 shares of the company were exchanged, compared to its average volume of 2,246,533. Relay Therapeutics, Inc. has a twelve month low of $1.77 and a twelve month high of $9.04. The firm has a market capitalization of $1.34 billion, a P/E ratio of -4.41 and a beta of 1.55. The company’s 50 day moving average price is $7.93 and its 200-day moving average price is $5.93.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, equities analysts expect that Relay Therapeutics, Inc. will post -2.55 EPS for the current year.

Hedge Funds Weigh In On Relay Therapeutics

Several hedge funds have recently modified their holdings of RLAY. Franklin Resources Inc. lifted its position in shares of Relay Therapeutics by 130.4% in the 2nd quarter. Franklin Resources Inc. now owns 394,122 shares of the company’s stock worth $1,364,000 after purchasing an additional 223,042 shares during the period. Congress Asset Management Co. increased its position in shares of Relay Therapeutics by 160.9% during the third quarter. Congress Asset Management Co. now owns 408,842 shares of the company’s stock worth $2,134,000 after buying an additional 252,142 shares during the period. Geode Capital Management LLC raised its stake in Relay Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock worth $11,176,000 after buying an additional 159,548 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Relay Therapeutics by 8,553.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 16,702 shares of the company’s stock worth $58,000 after acquiring an additional 16,509 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of Relay Therapeutics by 16.5% in the 2nd quarter. Acadian Asset Management LLC now owns 794,619 shares of the company’s stock valued at $2,747,000 after purchasing an additional 112,591 shares during the period. Institutional investors own 96.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RLAY. Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price for the company in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.